ArticleClinical and translational gastroenterology2015
C. difficile Infection: Changing Epidemiology and Management Paradigms.
Article in Clinical and translational gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 234 citations in OpenAlex.
- Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.World journal of gastroenterology · 2017Pooled it
- BeyondEmerging microbes & infections · 2026Article
- Colonization Dynamics ofVeterinary sciences · 2026Article
- Epidemiology, recurrence, and mortality in patients withPathogens and global health · 2026Article
- Risk Factors for Recurrence and In-Hospital Mortality in Patients withJournal of clinical medicine · 2025Article
- Genomic Characterization of Linezolid-ResistantBiotech (Basel (Switzerland)) · 2025Article
- Molecular Epidemiology ofAntibiotics (Basel, Switzerland) · 2025Article
- The Role ofMicroorganisms · 2025Review
- Article
- Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Comparison between Symptomatic and Asymptomatic Mice afterMicroorganisms · 2022Article
- Risk Factors of Patients With Diarrhea for HavingFrontiers in microbiology · 2022Article
- Article
- Toxin gene profiles and antimicrobial resistance ofIranian journal of microbiology · 2021Article
- Large Clostridial Toxins: Mechanisms and Roles in Disease.Microbiology and molecular biology reviews : MMBR · 2021Review
- Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.Clinical drug investigation · 2021Article
- High Prevalence of Clostridium difficile in Home Gardens in Western Australia.Applied and environmental microbiology · 2020Article
- Development and validation of a simple and robust model to predict 30-day mortality in patients withBMJ open gastroenterology · 2020Article
- Diagnosing Clostridioides difficile infections with molecular diagnostics: multicenter evaluation of revogene C. difficile assay.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Role of Surgery inClinics in colon and rectal surgery · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of Clostridium difficile infection (CDI) has been rising in hospitals, long-term care facilities, and within the community. Cases have been more severe with more complications, deaths, and higher healthcare-associated costs. With the emergence of a hypervirulent strain of C. difficile and the increasing prevalence of community-acquired CDI among healthy patients without traditional risk factors, the epidemiology of C. difficile has been evolving. This changing epidemiology requires a change in management. Taking into account new risk factors for CDI and growing subpopulations of affected individuals, diagnostic, treatment, and prevention approaches need to be adjusted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.